Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.

ABSTRACT:

Background

Antimicrobial peptides (AMPs) protect the host intestinal mucosa against microorganisms. Abnormal expression of defensins was shown in inflammatory bowel disease (IBD), but it is not clear whether this is a primary defect. We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD.

Methodology/principal findings

Mucosal gene expression of 81 AMPs was assessed in 61 IBD patients before and 4-6 weeks after their first infliximab infusion and in 12 control patients, using Affymetrix arrays. Quantitative real-time reverse-transcription PCR and immunohistochemistry were used to confirm microarray data. The dysregulation of many AMPs in colonic IBD in comparison with control colons was widely restored by inflixi

SUBMITTER: Arijs I 

PROVIDER: S-EPMC2776509 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature